Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Farletuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Farletuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Farletuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Farletuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Farletuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Farletuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Farletuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Farletuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Farletuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Farletuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Farletuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Farletuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Farletuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Farletuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Farletuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Farletuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Farletuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Farletuzumab. |
| Equol | Equol may increase the thrombogenic activities of Farletuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Farletuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Farletuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Farletuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Farletuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Farletuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Farletuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Farletuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Farletuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Farletuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Farletuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Farletuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Farletuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Farletuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Farletuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Farletuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Farletuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Farletuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Farletuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Farletuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Farletuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Farletuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Farletuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Farletuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Farletuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Farletuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Farletuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Farletuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Farletuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Farletuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Farletuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Farletuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Farletuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Farletuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Farletuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Farletuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Farletuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Farletuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Farletuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Farletuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Farletuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Farletuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Farletuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Farletuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Farletuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Farletuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Farletuzumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Farletuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Farletuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Farletuzumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Farletuzumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Farletuzumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Farletuzumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Farletuzumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Farletuzumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Farletuzumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Farletuzumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Farletuzumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Farletuzumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Farletuzumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Farletuzumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Farletuzumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Farletuzumab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Farletuzumab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Farletuzumab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Farletuzumab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Farletuzumab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Farletuzumab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Farletuzumab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Canakinumab. |